FindTrial
Sign In

Fam-Trastuzumab Deruxtecan-Nxki

DRUG3 trials

Sponsors

Strata Oncology, Enliven Therapeutics, QuantumLeap Healthcare Collaborative

Conditions

Advanced Solid TumorCancerER Positive Breast CancerEstrogen Receptor Positive TumorHER-2 Protein OverexpressionHER2 AmplificationHER2 Gene MutationHER2 Low Breast Cancer

Phase 1

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
Active, not recruitingNCT05650879
Enliven TherapeuticsHER2 Amplification, HER2 Gene Mutation, HER2 Mutant Non-small Cell Lung Cancer +1
Start: 2023-03-20End: 2026-07-31Target: 198Updated: 2025-07-15
PRE-I-SPY Phase I/Ib Oncology Platform Program
RecruitingNCT05868226
QuantumLeap Healthcare CollaborativeER Positive Breast Cancer, Estrogen Receptor Positive Tumor, HER2 Low Breast Cancer +18
Start: 2023-02-15End: 2029-12-30Target: 124Updated: 2025-04-04

Phase 2

StrataPATH™ (Precision Indications for Approved Therapies)
TerminatedNCT05097599
Strata OncologyAdvanced Solid Tumor, Cancer
Start: 2022-04-29End: 2024-06-12Updated: 2025-01-08

Related Papers

Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
Clinical Cancer Research2026-02-17
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).
Journal of Clinical Oncology2024-06-011 citations
Abstract CT059: StrataPATHTM: a multicohort, non-randomized, open-label phase 2 trial to explore efficacy and safety of FDA-approved cancer therapies in novel biomarker-guided patient population
Cancer Research2023-04-14